Skip to main content
. 2015 Aug 6;6(28):24947–24968. doi: 10.18632/oncotarget.4453

Figure 4. Tumor-homing ability of anti-EpCAM mAb in human colon cancer xenografts.

Figure 4

A. The expression level of EpCAM on cancer cell surfaces was determined by flow cytometry analysis using EpAb2-6-HL750. HL750 and NM-IgG-HL750 were used as controls. B. In vivo imaging of SCID mice bearing HCT116 human colon tumor xenografts was performed after intravenous injection of EpAb2-6-HL750, NM-IgG-HL750, or HL750. NIR fluorescence images were acquired at 48 hours post-injection (top). Red circles indicate the tumor loci. The signal intensity of the tumor area was quantified using IVIS software. Tumor distributions of EpAb2-6-HL750, NM-IgG-HL750, and HL750 at 72 hours post-injection are shown. Signal intensities for the tumor and organs were measured using IVIS software. Error bars show mean ± SD (n = 3) (Student's t-test, **p < 0.01) (below).